Doctor’s Passport

Find your next topic

Explore the current textbook

Available drafts · Clinical review pending
Membership
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
RapidMLAPSAMSRAMRCPMRCGP

Prescribing in kidney and liver disease

Essential points for quick revision.

Saved on this device

Synopsis

Translate kidney and liver assessment into an individual medicine plan, distinguishing stable impairment from acute deterioration and dose adjustment from treatment interruption.

  • Use the renal measure required by the specific medicine: laboratory eGFR and Cockcroft–Gault creatinine clearance are not interchangeable for every dosing decision, particularly with DOACs.
  • Check the age, current weight, creatinine value, units and clinical stability before accepting a calculated clearance. Creatinine-based estimates become unreliable during rapidly changing acute kidney injury.
  • For stable renal function using creatinine in micromol/L, Cockcroft–Gault clearance in mL/min is (140 − age) × weight × 1.23 / creatinine for men, or × 1.04 for women; extremes of body composition need careful interpretation.

Reasoning priorities

01
Serial kidney function and urine output

Assess the degree and trajectory of renal impairment.

Use a result recent enough for the clinical situation. The creatinine lags behind a sudden change, so urine output and physiology can identify deterioration before a new steady state exists. Repeat testing should be timed to the risk and linked to a clear plan for handling doses while the trajectory remains uncertain.

Worked reasoning

Worked caseResolve a renal estimate before prescribing

A 79-year-old woman weighs 50 kg and has stable creatinine of 100 micromol/L; the laboratory eGFR is 51 mL/min/1.73 m². A proposed medicine requires Cockcroft–Gault clearance for dosing, and its supplied dose table changes below 40 mL/min.

  1. Confirm that creatinine is stable and the measured 50 kg weight is a reasonable input for this patient. Identify the required output as creatinine clearance in mL/min; the reported indexed eGFR cannot simply be copied into the product table.
  2. Calculate the age term: 140 − 79 = 61 years. Multiply 61 × 50 × 1.04 = 3,172, then divide by creatinine 100 micromol/L to obtain an estimated clearance of 31.72 mL/min.
  3. Compare 31.72 with the supplied 40 mL/min boundary and use the below-40 dosing category for the next product-specific decision. Do not invent a dose from the clearance alone: the exact agent, indication and complete dose table remain necessary.
  4. Independently check by estimating 61 × 50 is about 3,000 and division by about 100 should yield roughly 30, not 300. Record the inputs, method, result and final action to use the lower-clearance category, then verify the actual product regimen before signing.
Acute illnessManage medicines during evolving kidney injury

A patient with a previously stable regimen develops dehydration and rising creatinine.

Key medicines

Metformin prolonged release in stable renal impairmentAt GFR 30–44 mL/min, the selected product permits no more than 1,000 mg orally per day and an initial dose no higher than 500 mg daily; it is contraindicated below GFR 30.Review dehydration, sepsis, hypoxia, hepatic insufficiency and excess alcohol as separate lactic-acidosis risks. A stable chronic category cannot justify continuing unchanged through serious acute illness; formulation and total daily exposure must be checked.
Amlodipine when kidney and liver function differThe ordinary adult oral starting regimen is 5 mg once each day, with 10 mg daily as the usual ceiling. Renal impairment alone does not require dose adjustment; liver impairment calls for cautious selection and slow titration.Monitor pressure, dizziness and oedema, with particular care in older adults and hepatic impairment. Severe hypotension or shock remains a contraindication regardless of the numerical kidney-function estimate.
Open full textbook Answer 2 questions
Sources and review status8 sources · checked 7 Sept 2026 · clinical review pending
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 7 Sept 2026; clinical approval remains outstanding.

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom